<DOC>
	<DOCNO>NCT01574170</DOCNO>
	<brief_summary>This biomedical study interventional type . The trial include 270 patient ( 180 patient first cohort 90 patient second cohort ) period 3 year + 2 year follow . This prospective study conduct patient receive third line chemotherapy metastatic breast cancer . The main objective study ( first cohort ) identify patient benefit third line treatment term overall survival score establish clinical , histological , also biological `` classic '' `` innovative '' ( account circulate tumor cell ) criterion , criterion must measurable introduction 3rd line . This score validate 2nd cohort . There interruption inclusion first second cohort patient</brief_summary>
	<brief_title>Prospective Construction Validation Prognostic Score Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From Third Line Chemotherapy Terms Overall Survival</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Women 18 year old 2. WHO 04 3 . Metastatic breast cancer 4 . Progression two line chemotherapy treatment decision investigator start thirdline chemotherapy 5 . Evaluable disease 6 . Histology : breast carcinoma whatever histological type , grade , hormone receptor expression HER2 7 . Patient able complete EORTC PAL 15 Questionnaire 8 . Patient member national insurance scheme 9 . Informed consent obtain sign patient 1 . History ( ) cancer ( ) potentially metastatic ( ) 2 . Woman participate third line chemotherapy clinical trial 3 . Pregnant woman nurse mother participate study 4 . Patient legal guardianship 5 . Patient unable undergo medical test various reason include social psychological reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Breast cancer ,</keyword>
	<keyword>Third line metastatic</keyword>
	<keyword>Chemotherapy ,</keyword>
	<keyword>Overall survival ,</keyword>
	<keyword>Quality life .</keyword>
</DOC>